CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞效力：从结构元件到载体骨架组件
英文原题：CAR-T cell potency: from structural elements to vector backbone components.
查看英文原题
CAR-T cell potency: from structural elements to vector backbone components.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法通过改造患者自身的T淋巴细胞使其能够识别并杀伤癌细胞，在部分血液系统恶性肿瘤的临床前和临床试验中取得了显著成功，目前已有六种FDA批准的CAR-T 产品上市。一旦装备了CAR构建体，T细胞便充当活体药物，以MHC非依赖的方式识别并清除靶肿瘤细胞。在本综述中，我们首先详细描述了CAR的所有结构模块，重点关注较新的发现。随后，我们指出了影响CAR表达的幕后因素，并综述了嵌入病毒载体骨架中的元件如何能够显著影响CAR的表达。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market.
Once equipped with a CAR construct, T cells act as living drugs and recognize and eliminate the target tumor cells in an MHC-independent manner. In this review, we first described all structural modular of CAR in detail, focusing on more recent findings.
We then pointed out behind-the-scene elements contributing to CAR expression and reviewed how CAR expression can be drastically affected by the elements embedded in the viral vector backbone.
论文信息
- 作者
- Mazinani M、Rahbarizadeh F
- 第一作者单位
- Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-111, Tehran, Iran.Iran
- 通讯作者单位
- Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-111, Tehran, Iran. rahbarif@modares.ac.ir.Iran
- 文献类型
- 综述
- 期刊
- Biomarker research2022 Sep 19
- 原文标识
- PubMed 36123710 · DOI 10.1186/s40364-022-00417-w
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →